Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 86Neoplasm Metastasis 75Colorectal Neoplasms 74Neoplasms 70Leukemia, Myeloid, Acute 61Breast Neoplasms 57Multiple Myeloma 48Prostatic Neoplasms 47Ovarian Neoplasms 44Squamous Cell Carcinoma of Head and Neck 39Pancreatic Neoplasms 39Melanoma 36Recurrence 34Triple Negative Breast Neoplasms 31Lymphoma, Non-Hodgkin 31Lung Neoplasms 31Glioblastoma 30Myelodysplastic Syndromes 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Endometrial Neoplasms 27Advanced Solid Tumors 27Stomach Neoplasms 25Carcinoma, Renal Cell 25Small Cell Lung Carcinoma 24Sarcoma 23Carcinoma, Hepatocellular 21Brain Neoplasms 21Lymphoma, Large B-Cell, Diffuse 19Esophageal Neoplasms 19Lymphoma, B-Cell 17

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphangioleiomyomatosis × 30 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡